National and Kapodistrian University of Athens
Τα miRNAs και γενετικοί πολυμορφισμοί ως νέοι δείκτες διάγνωσης και πρόγνωσης για το οξύ έμφραγμα του μυοκαρδίου
Abstract
dc:descriptionCardiovascular diseases (CVD) are the most common cause of death worldwide. Current research in the field of CVD aims to explore new diagnostic and/or prognostic biomarkers for their accurate and timely diagnosis, leading to immediate treatment of those patients and reduced morbidity and mortality rates. Necrosis and apoptosis of the myocardial cells that take place during acute myocardial infarction (AMI) result in the release of intracellular molecules, such as proteins and free nucleic acids (DNA/RNA), in the bloodstream. MicroRNAs (miRNAs-miRs) are small non-coding RNA molecules, 21-23 nucleotides in length, that regulate gene expression in eukaryotic organisms, either by inhibiting translation or promoting the degradation of specific RNAs (mRNAs). MiRs could be used for the early diagnosis of AMI, as they exhibit high stability in biological fluids and can be quantified by sensitive techniques. In addition, cell free DNA (cfDNA) could also consist a sensitive and reliable diagnostic AMI marker. Genetic factors also display an essential role as risk factors for the progress of CVD. Genetic polymorphisms in microRNA genes appear to affect their function and possibly contribute to the advance of these multifactorial diseases. The goal of the present PhD thesis is to investigate novel biomarkers that could be used for the early and accurate diagnosis of CVD, such as coronary artery disease (CAD) and AMI. Specifically, the three main axes of this thesis are: a) to quantitatively compare the expression levels of miR-208b and miR-499, which are associated with the cardiac function, in AMI patients and healthy individuals of the general population, b) to estimate the role of whole cfDNA, isolated from the plasma of AMI patients, as a biological marker for the early diagnosis of their condition, and c) to investigate the genetic polymorphisms (SNPs) miR146a G>C (rs2910164), miR149 C>T (rs2292832), miR196a2 C>T (rs11614913) and miR499 A>G (rs3746444) and their potential contribution in CAD and AMI prevalence. In the current study, samples derived from 400 individuals of Greek origin were analyzed: 200 CAD patients, 80 patients diagnosed with AMI and 200 healthy people of the general population, who served as the control group. Quantitative Real-Time PCR (qPCR) was used to quantify miR-208b and miR-499. The quantification of cfDNA was performed according to the following methods: 1) fluorescence reaction with Qubit 3.0 using ssDNA (single strand) assay kit and dsDNA HS (double strand) assay kit, 2) UV spectrophotometry using Nanodrop and 3) qPCR using TaqMan™ Copy Number Reference Assay, human, TERT. The quantification of cfDNA was made using different techniques, in order to evaluate their clinical application. The examination of the potential role of miR146a G>C (rs2910164), miR149 C>T (rs2292832), miR196a2 C>T (rs11614913) and miR499 A>G (rs3746444) genetic polymorphisms in the progress of CVD required comparative analysis of patient and control groups. Genotyping of patients and healthy subjects was executed using the following methodologies: 1) PCR-RFLP (Polymerase Chain Reaction-Restriction Fragment Length Polymorphism), 2) High Resolution Melting Analysis (HRMA) and 3) Sanger sequencing. The results of this PhD thesis show that the relative expression of miR-208b and miR-499 microRNAs is dramatically increased in AMI patients compared with that observed in healthy controls (p<0.001). Specifically, in the patient group, plasma levels of miR-208b and miR-499 are augmented 256-fold and 675-fold, respectively. To evaluate the differential diagnosis of plasma circulating miR-208b and miR-499 in the diagnosis of AMI, the ROC curve is calculated. The area under the curve (AUC) of miR-208b is 0.9996 and of miR- 499 is 0.9992. The AUC of the two established biomarkers for the AMI diagnosis, cardiac troponin T (cTnT) and creatine kinase isoenzyme (CK-MB), whose plasma elevation is detected 4 to 6 hours following AMI, was 0.9400 and 0.9944, respectively; thereby highlighting the strong diagnostic value of these two microRNAs in clinical cardiology. The concentration of cf-DNA in the plasma of AMI patients was significantly higher than that of healthy controls (p<0.05). Quantification, using ss-DNA, presents the highest concentrations of cf-DNA, compared to those recorded using ds-DNA and NanoDrop. These measurements approach the values reported by the qPCR methodology, which is an accurate, but expensive and time consuming technique. Finally, the results of this PhD thesis reveal that there is a statistically significant difference in the genotypes and alleles frequencies among CAD/AMI and control groups (p<0.05) for miR196a2 C>T (rs11614913) and miR499 A>G (rs3746444) microRNA polymorphisms. For miR146a rs2910164G>C and miR149 rs2292832C> T polymorphisms, no statistically significant difference is observed among CAD/AMI patients and healthy individuals both for genotype and allele frequencies (p>0.05). The combinatorial study of the four polymorphisms (using Haploview program) indicates a statistically significant difference for the miR-499G -miR196T-miR146C-miR149C combination (p=0.0487), with a higher frequency in the group of patients diagnosed with CAD/AMI. In conclusion, miR-208b and miR-499 microRNAs could consist significant biomarkers for the valid and timely diagnosis of patients suffering from AMI. Their application as AMI biomarkers is more accurate, faster, and less expensive than the methodologies applied to date. Free extracellular DNA could also be considered as a biomarker for the diagnosis of AMI. Its quantification could be performed simply and rapidly using more cost-effective methodologies than qPCR. Moreover, miR196a2 (rs11614913) and miR499 (rs3746444) polymorphisms, and the haplotype miR-499G-miR196T-miR146C-miR149C seem to act as risk factors for CVD occurrence in the Greek population. Therefore, the results of this thesis, individually or combinatorially, are expected to contribute to the suggestion of new biomarkers for AMI and to the clarification of the role of genetic polymorphisms of specific microRNAs as risk factors for CVD.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Agiannitopoulos, Konstantnos
- Αγιαννιτόπουλος, Κωνσταντίνος
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46571